The result will be more competition, lower prices, and faster access to life saving medicines. And we know this approach works. Since 2015, biosimilars have already saved Americans over $56 billion, 20 billion in 2024 alone. On average, biosimilars cost 50% less than their brand name counterparts. And their entry into the market drives down brand name prices by another 25%. That's real relief for patients, families, and for the American taxpayer. (06:13–06:20)
CLAIM
Asserts that biosimilars are generally half the cost of brand-name drugs.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
